First Foundation Advisors Has $725,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Foundation Advisors increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 168.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,457 shares of the medical research company’s stock after acquiring an additional 914 shares during the quarter. First Foundation Advisors’ holdings in Thermo Fisher Scientific were worth $725,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. S&CO Inc. lifted its stake in Thermo Fisher Scientific by 7.5% in the first quarter. S&CO Inc. now owns 41,872 shares of the medical research company’s stock valued at $20,835,000 after buying an additional 2,911 shares during the period. Banque Cantonale Vaudoise acquired a new position in Thermo Fisher Scientific in the first quarter valued at approximately $4,042,000. Geneos Wealth Management Inc. lifted its stake in Thermo Fisher Scientific by 16.9% in the first quarter. Geneos Wealth Management Inc. now owns 4,969 shares of the medical research company’s stock valued at $2,473,000 after buying an additional 718 shares during the period. N.E.W. Advisory Services LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at approximately $110,000. Finally, TCTC Holdings LLC increased its holdings in shares of Thermo Fisher Scientific by 36.8% during the first quarter. TCTC Holdings LLC now owns 186 shares of the medical research company’s stock valued at $93,000 after acquiring an additional 50 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.5%

Shares of NYSE TMO opened at $482.75 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business’s fifty day moving average price is $416.56 and its 200-day moving average price is $468.86. The stock has a market capitalization of $182.23 billion, a PE ratio of 27.92, a P/E/G ratio of 2.59 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays boosted their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. UBS Group boosted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Finally, Argus decreased their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.